Engineering Fc Antibody Regions to Confer Effector Function

Abstract

The present invention relates to molecules having a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region. These modified molecules confer an effector function to a molecule, where the parent molecule does not detectably exhibit this effector function. In one embodiment, the variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention have particular utility in treatment, prevention or management of a disease or disorder, in a sub-population of patients, wherein the target antigen is expressed at low levels in the target cell population.

1 . A modified antibody that binds a CD32B antigen, said modified antibody comprising a variant human IgG1 Fc region, wherein said variant human IgG1 Fc region comprises at least one amino acid modification relative to the human IgG1 Fc region of a parent antibody that binds said antigen, said amino acid modification(s) comprising amino acid modification(s) that alter the affinity or avidity of the variant Fc region for binding to an FcγR such that said modified antibody is therapeutically effective in a patient refractory to treatment with said parent antibody, said amino acid modification(s) that alter the affinity or avidity of the variant Fc region for binding to an FcγR consisting of the modification of 1, 2, 3, 4 or 5 amino acid residues of the IgG1 Fc region of said parent antibody. 
     
     
         2 . The modified antibody of  claim 1 , wherein said modified antibody exhibits, in an in vitro assay, detectable effector function activity in cells derived from said patient, which cells are positive for said antigen, and said parent antibody does not exhibit detectable function activity in said cells using said in vitro assay. 
     
     
         3 . The modified antibody of  claim 1 , wherein said amino acid modification(s) that alter the affinity or avidity of the variant Fc region for binding to an FcγR comprise(s) a substitution:
 (i) at position 370 with glutamic acid, at position 396 with leucine and at position 270 with glutamic acid; 
 (ii) at position 419 with histidine, at position 396 with leucine and at position 270 with glutamic acid; 
 (iii) at position 240 with alanine, at position 396 with leucine and at position 270 with glutamic acid; 
 (iv) at position 255 with leucine, at position 396 with leucine and position 270 with glutamic acid; 
 (v) at position 255 with leucine, at position 396 with leucine, at position 270 with glutamic acid and at position 292 with glycine; or 
 (vi) at position 255 with leucine, at position 396 with leucine, at position 270 with glutamic acid and at position 300 with leucine. 
 
     
     
         4 . The modified antibody of  claim 1 , wherein at least one of said amino acid modification(s) that alter the affinity or avidity of the variant Fc region for binding to an FcγR is in a CH2 domain of said variant human IgG1 Fc region. 
     
     
         5 . The modified antibody of  claim 4 , wherein said amino acid modification(s) that alter the affinity or avidity of the variant Fc region for binding to an FcγR in said CH2 domain comprises a substitution at position 240, 243, 247, 255, 270, 292, or 300 with another amino acid at that position. 
     
     
         6 . The modified antibody of  claim 1 , wherein at least one of said amino acid modification(s) that alter the affinity or avidity of the variant Fc region for binding to an FcγR is in a CH3 domain of said variant human IgG1 Fc region. 
     
     
         7 . The modified antibody of  claim 6 , wherein said amino acid modification(s) that alter the affinity or avidity of the variant Fc region for binding to an FcγR in said CH3 domain comprises a substitution at position 370, 392, 396, 419, or 421 with another amino acid at that position. 
     
     
         8 . The modified antibody of  claim 1 , wherein said amino acid modification(s) that alter the affinity or avidity of the variant Fc region for binding to an FcγR comprises at least one amino acid modification in the CH2 domain and at least one amino acid modification in the CH3 domain of the Fc region. 
     
     
         9 . The modified antibody of  claim 1 , wherein said amino acid modification(s) that alter the affinity or avidity of the variant Fc region for binding to an FcγR is in the hinge region of the human IgG1 heavy chain. 
     
     
         10 . The modified antibody of  claim 8 , comprising at least one amino acid modification that alters the affinity or avidity of the variant Fc region for binding to an FcγR in the hinge region of the human IgG1 heavy chain. 
     
     
         11 . The modified antibody of  claim 1  which variant IgG1 Fc region specifically binds FcγRIIIA with a greater affinity than said parent antibody binds FcγRIIIA. 
     
     
         12 . The modified antibody of  claim 1  which variant IgG1 Fc region specifically binds FcγRIIA with a greater affinity than said parent antibody binds FcγRIIA. 
     
     
         13 . The modified antibody of  claim 1  which variant IgG1 Fc region specifically binds FcγRIIB with a lower affinity than said parent antibody binds FcγRIIB. 
     
     
         14 . The modified antibody of  claim 11  which variant IgG1 Fc region specifically binds FcγRIIB with a lower affinity than said parent antibody binds FcγRIIB. 
     
     
         15 . The modified antibody of  claim 12  which variant IgG1 Fc region specifically binds FcγRIIB with a lower affinity than said parent antibody binds FcγRIIB. 
     
     
         16 . The modified antibody of  claim 1  which detectably binds cells positive for said antigen, which antigen is expressed at a density of 200 to 1,000 molecules/cell on said cells. 
     
     
         17 . The modified antibody of  claim 2  wherein said effector function is antibody dependent cell-mediated cell cytotoxicity (ADCC). 
     
     
         18 . The modified antibody of  claim 2  wherein said effector function is phagocytosis, opsonization, cell binding, rosetting, complement dependent cell mediated cytotoxicity (CDC), or antibody dependent cell-mediated cell cytotoxicity (ADCC). 
     
     
         19 . The modified antibody of  claim 2  wherein said in vitro assay is performed using effector cells and target cells, under conditions in which the effector cell:target cell ratio is 10:1. 
     
     
         20 . The modified antibody of  claim 1  which is a monoclonal antibody. 
     
     
         21 . The modified antibody of  claim 1  which is a chimeric, human or humanized antibody. 
     
     
         22 . The modified antibody of  claim 1 , in which the parent antibody has immunomodulatory activity. 
     
     
         23 . A pharmaceutical composition comprising the modified antibody of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         24 . The modified antibody of  claim 1 , wherein said amino acid modification(s) that alter the affinity or avidity of the variant Fc region for binding to an FcγR consist of the modification of 1, 2 or 3 amino acid residues of the IgG1 Fc region of said parent antibody. 
     
     
         25 . The modified antibody of  claim 1 , wherein said amino acid modification(s) that alter the affinity or avidity of the variant Fc region for binding to an FcγR consist of the modification of 4 or 5 amino acid residues of the IgG1 Fc region of said parent antibody. 
     
     
         26 . The modified antibody of  claim 2 , wherein said in vitro assay is performed using effector cells and target cells, under conditions in which the effector cell:target cell ratio is 30:1. 
     
     
         27 . The modified antibody of  claim 2  wherein said in vitro assay is performed using effector cells and target cells, under conditions in which the effector cell:target cell ratio is 50:1. 
     
     
         28 . The modified antibody of  claim 2  wherein said in vitro assay is performed using effector cells and target cells, under conditions in which the effector cell:target cell ratio is 75:1. 
     
     
         29 . The modified antibody of  claim 2  wherein said in vitro assay is performed using effector cells and target cells, under conditions in which the effector cell:target cell ratio is 100:1. 
     
     
         30 . The modified antibody of  claim 1 , wherein said modified antibody exhibits, in an in vitro assay, detectable cell killing in cells positive for said antigen, and said parent antibody does not exhibit detectable cell killing in said cells using said in vitro assay. 
     
     
         31 . The modified antibody of  claim 30  wherein said in vitro assay is performed using effector cells and target cells, under conditions in which the effector cell:target cell ratio is 10:1. 
     
     
         32 . The modified antibody of  claim 30  wherein said in vitro assay is performed using effector cells and target cells, under conditions in which the effector cell:target cell ratio is 30:1. 
     
     
         33 . The modified antibody of  claim 30  wherein said in vitro assay is performed using effector cells and target cells, under conditions in which the effector cell:target cell ratio is 50:1. 
     
     
         34 . The modified antibody of  claim 30  wherein said in vitro assay is performed using effector cells and target cells, under conditions in which the effector cell:target cell ratio is 75:1. 
     
     
         35 . The modified antibody of  claim 30  wherein said in vitro assay is performed using effector cells and target cells, under conditions in which the effector cell:target cell ratio is 100:1.